Spruce Biosciences (SPRB) Competitors $0.49 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SPRB vs. CLSD, CMRX, PDSB, IMAB, EPIX, AVTE, HOWL, VTGN, ZIVO, and OVIDShould you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Clearside Biomedical (CLSD), Chimerix (CMRX), PDS Biotechnology (PDSB), I-Mab (IMAB), ESSA Pharma (EPIX), Aerovate Therapeutics (AVTE), Werewolf Therapeutics (HOWL), Vistagen Therapeutics (VTGN), ZIVO Bioscience (ZIVO), and Ovid Therapeutics (OVID). These companies are all part of the "pharmaceutical products" industry. Spruce Biosciences vs. Clearside Biomedical Chimerix PDS Biotechnology I-Mab ESSA Pharma Aerovate Therapeutics Werewolf Therapeutics Vistagen Therapeutics ZIVO Bioscience Ovid Therapeutics Spruce Biosciences (NASDAQ:SPRB) and Clearside Biomedical (NASDAQ:CLSD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, community ranking, analyst recommendations and profitability. Which has preferable valuation and earnings, SPRB or CLSD? Clearside Biomedical has lower revenue, but higher earnings than Spruce Biosciences. Clearside Biomedical is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSpruce Biosciences$10.09M2.01-$47.92M-$0.94-0.52Clearside Biomedical$8.23M9.68-$32.49M-$0.45-2.33 Does the MarketBeat Community favor SPRB or CLSD? Clearside Biomedical received 329 more outperform votes than Spruce Biosciences when rated by MarketBeat users. Likewise, 67.52% of users gave Clearside Biomedical an outperform vote while only 60.00% of users gave Spruce Biosciences an outperform vote. CompanyUnderperformOutperformSpruce BiosciencesOutperform Votes3960.00% Underperform Votes2640.00% Clearside BiomedicalOutperform Votes36867.52% Underperform Votes17732.48% Which has more volatility & risk, SPRB or CLSD? Spruce Biosciences has a beta of 2.36, meaning that its share price is 136% more volatile than the S&P 500. Comparatively, Clearside Biomedical has a beta of 2.33, meaning that its share price is 133% more volatile than the S&P 500. Does the media refer more to SPRB or CLSD? In the previous week, Clearside Biomedical had 12 more articles in the media than Spruce Biosciences. MarketBeat recorded 12 mentions for Clearside Biomedical and 0 mentions for Spruce Biosciences. Clearside Biomedical's average media sentiment score of 0.65 beat Spruce Biosciences' score of -0.07 indicating that Clearside Biomedical is being referred to more favorably in the news media. Company Overall Sentiment Spruce Biosciences Neutral Clearside Biomedical Positive Do analysts recommend SPRB or CLSD? Spruce Biosciences currently has a consensus target price of $4.00, indicating a potential upside of 716.33%. Clearside Biomedical has a consensus target price of $5.33, indicating a potential upside of 407.94%. Given Spruce Biosciences' higher probable upside, research analysts clearly believe Spruce Biosciences is more favorable than Clearside Biomedical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spruce Biosciences 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Clearside Biomedical 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is SPRB or CLSD more profitable? Clearside Biomedical has a net margin of -413.83% compared to Spruce Biosciences' net margin of -555.23%. Clearside Biomedical's return on equity of 0.00% beat Spruce Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Spruce Biosciences-555.23% -62.10% -47.49% Clearside Biomedical -413.83%N/A -92.90% Do insiders & institutionals believe in SPRB or CLSD? 91.7% of Spruce Biosciences shares are held by institutional investors. Comparatively, 18.8% of Clearside Biomedical shares are held by institutional investors. 9.1% of Spruce Biosciences shares are held by company insiders. Comparatively, 9.2% of Clearside Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryClearside Biomedical beats Spruce Biosciences on 12 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Spruce Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SPRB vs. The Competition Export to ExcelMetricSpruce BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.06M$6.48B$5.05B$8.87BDividend YieldN/A8.12%4.97%4.06%P/E Ratio-0.525.5697.3414.18Price / Sales2.01348.141,218.4289.42Price / CashN/A22.1533.5132.79Price / Book0.397.885.805.12Net Income-$47.92M$153.61M$119.07M$225.99M7 Day Performance-5.95%-2.00%-1.83%-1.32%1 Month Performance-10.37%-7.47%-3.64%0.60%1 Year Performance-64.23%31.80%31.62%26.23% Spruce Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SPRBSpruce Biosciences2.9724 of 5 stars$0.49flat$4.00+716.3%-64.0%$20.06M$10.09M-0.5220CLSDClearside Biomedical3.0244 of 5 stars$1.05+1.9%$5.33+407.9%+8.1%$79.63M$8.23M-2.2930Analyst RevisionCMRXChimerix4.5147 of 5 stars$0.88flat$8.50+865.9%-12.0%$79.15M$320,000.00-0.9472Analyst ForecastPDSBPDS Biotechnology1.825 of 5 stars$2.03-3.3%$12.33+509.1%-67.9%$78.37MN/A0.0020IMABI-Mab2.5456 of 5 stars$0.98+3.2%$8.00+716.3%-37.6%$77.61M$3.89M0.0034Gap UpEPIXESSA Pharma2.7825 of 5 stars$1.73-0.6%$11.67+574.4%-68.0%$77.20MN/A0.0050AVTEAerovate Therapeutics1.7152 of 5 stars$2.66-0.4%$2.25-15.4%-81.7%$76.81MN/A-0.8951Positive NewsHOWLWerewolf Therapeutics3.4178 of 5 stars$1.64-1.8%$12.00+631.7%-33.6%$74.42M$19.94M0.0040Analyst ForecastVTGNVistagen Therapeutics3.774 of 5 stars$2.61-2.2%$15.00+474.7%-25.4%$74.34M$1.06M0.0040Positive NewsZIVOZIVO BioscienceN/A$20.96flatN/A+1,668.8%$74.33M$30,000.000.0010Negative NewsOVIDOvid Therapeutics4.4194 of 5 stars$1.04+1.0%$4.04+288.5%-68.5%$73.14M$390,000.000.0060Analyst RevisionNews Coverage Related Companies and Tools Related Companies Clearside Biomedical Competitors Chimerix Competitors PDS Biotechnology Competitors I-Mab Competitors ESSA Pharma Competitors Aerovate Therapeutics Competitors Werewolf Therapeutics Competitors Vistagen Therapeutics Competitors ZIVO Bioscience Competitors Ovid Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SPRB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spruce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Spruce Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
